WO1999055162A8 - Procede de traitement d'une maladie virale - Google Patents

Procede de traitement d'une maladie virale

Info

Publication number
WO1999055162A8
WO1999055162A8 PCT/US1998/008291 US9808291W WO9955162A8 WO 1999055162 A8 WO1999055162 A8 WO 1999055162A8 US 9808291 W US9808291 W US 9808291W WO 9955162 A8 WO9955162 A8 WO 9955162A8
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
mammal
viral disease
virus
antispermatozoal
Prior art date
Application number
PCT/US1998/008291
Other languages
English (en)
Other versions
WO1999055162A1 (fr
Inventor
T Ronald Theodore
Original Assignee
T Ronald Theodore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Ronald Theodore filed Critical T Ronald Theodore
Priority to AU71575/98A priority Critical patent/AU7157598A/en
Priority to PCT/US1998/008291 priority patent/WO1999055162A1/fr
Publication of WO1999055162A1 publication Critical patent/WO1999055162A1/fr
Publication of WO1999055162A8 publication Critical patent/WO1999055162A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé de traitement de maladies virales, en particulier de maladies causées par le virus du SIDA, et plus particulièrement par le VIH-1, chez un mammifère. Ce procédé consiste à administrer à un mammifère ayant ce virus une dose thérapeutiquement efficace d'un anticorps antispermatozoïde humain, ou d'anticorps monoclonaux dérivés de ceux-ci, utilisés seuls ou en combinaison avec du plasma, un sérum ou une immunoglobuline purifiée, et leurs combinaisons.
PCT/US1998/008291 1998-04-24 1998-04-24 Procede de traitement d'une maladie virale WO1999055162A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU71575/98A AU7157598A (en) 1998-04-24 1998-04-24 Method for the treatment of viral disease
PCT/US1998/008291 WO1999055162A1 (fr) 1998-04-24 1998-04-24 Procede de traitement d'une maladie virale

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/008291 WO1999055162A1 (fr) 1998-04-24 1998-04-24 Procede de traitement d'une maladie virale

Publications (2)

Publication Number Publication Date
WO1999055162A1 WO1999055162A1 (fr) 1999-11-04
WO1999055162A8 true WO1999055162A8 (fr) 2000-07-13

Family

ID=22266910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/008291 WO1999055162A1 (fr) 1998-04-24 1998-04-24 Procede de traitement d'une maladie virale

Country Status (2)

Country Link
AU (1) AU7157598A (fr)
WO (1) WO1999055162A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759545A (en) * 1996-02-27 1998-06-02 Theodore; T. Ronald Method for the treatment of HIV-I infection

Also Published As

Publication number Publication date
WO1999055162A1 (fr) 1999-11-04
AU7157598A (en) 1999-11-16

Similar Documents

Publication Publication Date Title
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
DK1140170T3 (da) Antistoffragmenter til topisk behandling af öjensygdomme
KR950005327A (ko) 임파구 항원 CD2 및 종양 항원을 인식하는 이특이적 트리거(Trigger) 분자
WO2004018649A3 (fr) Anticorps monoclonaux et regions determinantes de complementarite se liant a des glycoproteine ebola
WO2004022718A3 (fr) Anticorps monoclonal therapeutique anti-il-1r1 humain
EP1127170A4 (fr) Anticorps monoclonaux humains du virus de l'hepatite c (vhc) pan
DK0751781T3 (da) Anvendelse af monoklonale antistoffer eller oplöselige oligomere ligander til fremstillingen af et medikament til forebyggelse eller behandling af neoplastiske sygdomme
DE69636760D1 (de) Rekombinanter anti-cd4 antikörper zur menschlichen behandlung
WO2003043583A3 (fr) Traitement des troubles immunologiques au moyen des anticorps anti-cd30
PL401886A1 (pl) Neutralizujace o wysokim powinowactwie izolowane ludzkie przeciwcialo anty-TNF-alfa, zastosowanie tego przeciwciala, krysztal zawierajacy ludzkie przeciwcialo anty-TNF-alfa i preparat zawierajacy ten krysztal
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
AT500379A3 (de) Tau-proteine
AU3045497A (en) Human monoclonal antibody against hepatitis b virus surface antigen (hbvsag)
WO2001058485A3 (fr) Anticorps monoclonaux a vocation prophylactique et therapeutique
EA200401081A1 (ru) Fab-фрагменты моноклонального антитела человека, направленные против гликопротеина e2 hcv и обладающие нейтрализующей активностью in vitro
EP0350690A3 (fr) Neutralisation des propriétés toxiques in vitro et in vivo du TNF-alfa par anticorps monoclonaux et fragments dérivés
AU6819600A (en) Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections
EA200400134A1 (ru) Терапевтический агент
DE69636527D1 (de) Antigenes protein aus malassezia
CA2412460A1 (fr) Anticorps monoclonal humain contre la glycoproteine e2 du virus de l'hepatite c
ATE472337T1 (de) Pharmazeutische zusammensetzung aus f(ab) 2- fragmenten von antikörpern und verfahren zu ihrer herstellung
WO1999055162A8 (fr) Procede de traitement d'une maladie virale
WO2005049635A3 (fr) Anticorps monoclonal humain reducteur de graisse
WO2003097082A3 (fr) Traitement de la maladie de crohn ou du psoriasis a partir d'anticorps anti-interferon gamma
CA2606022A1 (fr) Procedes d'application de rayons d'ionisation pour la therapie de l'infection vih

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: (EXCEPT CN, IL, KR, NO, RU, SG)

AK Designated states

Kind code of ref document: C1

Designated state(s): AU CA CN IL JP KR MX NO RU SG US

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 44/99 UNDER (81) ADD "CN, IL, KR, NO, RU, SG"; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: CA